Phase I study to determine the maximum tolerated dose of ET-743 (yondelis) [trabectedin] and capecitabine administered to patients with advanced breast cancer
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2006
At a glance
- Drugs Capecitabine; Trabectedin
- Indications Advanced breast cancer
- Focus Adverse reactions
- 19 Jan 2006 New trial record.